184 related articles for article (PubMed ID: 19073596)
1. MAFbx/Atrogin-1 controls the activity of the initiation factor eIF3-f in skeletal muscle atrophy by targeting multiple C-terminal lysines.
Csibi A; Leibovitch MP; Cornille K; Tintignac LA; Leibovitch SA
J Biol Chem; 2009 Feb; 284(7):4413-21. PubMed ID: 19073596
[TBL] [Abstract][Full Text] [Related]
2. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Lagirand-Cantaloube J; Offner N; Csibi A; Leibovitch MP; Batonnet-Pichon S; Tintignac LA; Segura CT; Leibovitch SA
EMBO J; 2008 Apr; 27(8):1266-76. PubMed ID: 18354498
[TBL] [Abstract][Full Text] [Related]
3. eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.
Csibi A; Tintignac LA; Leibovitch MP; Leibovitch SA
Cell Cycle; 2008 Jun; 7(12):1698-701. PubMed ID: 18583931
[TBL] [Abstract][Full Text] [Related]
4. eIF3f: a central regulator of the antagonism atrophy/hypertrophy in skeletal muscle.
Sanchez AM; Csibi A; Raibon A; Docquier A; Lagirand-Cantaloube J; Leibovitch MP; Leibovitch SA; Bernardi H
Int J Biochem Cell Biol; 2013 Oct; 45(10):2158-62. PubMed ID: 23769948
[TBL] [Abstract][Full Text] [Related]
5. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.
Castillero E; Alamdari N; Lecker SH; Hasselgren PO
Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982
[TBL] [Abstract][Full Text] [Related]
6. Identification of essential sequences for cellular localization in the muscle-specific ubiquitin E3 ligase MAFbx/Atrogin 1.
Julie LC; Sabrina BP; Marie-Pierre L; Leibovitch SA
FEBS Lett; 2012 Feb; 586(4):362-7. PubMed ID: 22249105
[TBL] [Abstract][Full Text] [Related]
7. FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.
Mei Z; Zhang D; Hu B; Wang J; Shen X; Xiao W
J Biol Chem; 2015 Jun; 290(26):16202-14. PubMed ID: 25944903
[TBL] [Abstract][Full Text] [Related]
8. The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy in mouse.
Csibi A; Cornille K; Leibovitch MP; Poupon A; Tintignac LA; Sanchez AM; Leibovitch SA
PLoS One; 2010 Feb; 5(2):e8994. PubMed ID: 20126553
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.
Bodine SC; Baehr LM
Am J Physiol Endocrinol Metab; 2014 Sep; 307(6):E469-84. PubMed ID: 25096180
[TBL] [Abstract][Full Text] [Related]
10. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
11. Posttranslational modifications control FoxO3 activity during denervation.
Bertaggia E; Coletto L; Sandri M
Am J Physiol Cell Physiol; 2012 Feb; 302(3):C587-96. PubMed ID: 22094330
[TBL] [Abstract][Full Text] [Related]
12. Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting.
Lokireddy S; Wijesoma IW; Sze SK; McFarlane C; Kambadur R; Sharma M
Am J Physiol Cell Physiol; 2012 Sep; 303(5):C512-29. PubMed ID: 22673621
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo.
Lagirand-Cantaloube J; Cornille K; Csibi A; Batonnet-Pichon S; Leibovitch MP; Leibovitch SA
PLoS One; 2009; 4(3):e4973. PubMed ID: 19319192
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
15. Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy.
Iyer CC; McGovern VL; Wise DO; Glass DJ; Burghes AH
Neuromuscul Disord; 2014 May; 24(5):436-44. PubMed ID: 24656734
[TBL] [Abstract][Full Text] [Related]
16. Effect of dexamethasone on the expression of atrogin-1/MAFbx in chick skeletal muscle.
Nakashima K; Ishida A; Ijiri D; Ohtsuka A
Anim Sci J; 2016 Mar; 87(3):405-10. PubMed ID: 26279163
[TBL] [Abstract][Full Text] [Related]
17. A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure.
Watson ML; Baehr LM; Reichardt HM; Tuckermann JP; Bodine SC; Furlow JD
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1210-20. PubMed ID: 22354783
[TBL] [Abstract][Full Text] [Related]
18. Flavones Inhibit LPS-Induced Atrogin-1/MAFbx Expression in Mouse C2C12 Skeletal Myotubes.
Shiota C; Abe T; Kawai N; Ohno A; Teshima-Kondo S; Mori H; Terao J; Tanaka E; Nikawa T
J Nutr Sci Vitaminol (Tokyo); 2015; 61(2):188-94. PubMed ID: 26052151
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice.
Cong H; Sun L; Liu C; Tien P
Hum Gene Ther; 2011 Mar; 22(3):313-24. PubMed ID: 21126200
[TBL] [Abstract][Full Text] [Related]
20. Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression.
Fareed MU; Evenson AR; Wei W; Menconi M; Poylin V; Petkova V; Pignol B; Hasselgren PO
Am J Physiol Regul Integr Comp Physiol; 2006 Jun; 290(6):R1589-97. PubMed ID: 16455766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
